Loading...
Loading...
CPRX| Name | Value |
|---|---|
| Revenues | 98.5M |
| Cost of Revenue | 12.5M |
| Gross Profit | 86.0M |
| Operating Expense | 58.9M |
| Operating I/L | 27.1M |
| Other Income/Expense | 2.0M |
| Interest Income | 0.0M |
| Pretax | 29.1M |
| Income Tax Expense | 5.8M |
| Net Income/Loss | 23.3M |
Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company specializing in developing and commercializing therapies for rare neuromuscular and neurological diseases. Their flagship product, Firdapse, is an amifampridine phosphate tablet used to treat Lambert-Eaton myasthenic syndrome (LEMS) and pediatric LEMS patients. The company also has ongoing development for the treatment of MuSK antibody positive myasthenia gravis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. Catalyst Pharmaceuticals, Inc. generates revenue through the sales of Firdapse and Ruzurgi, as well as through license agreements with other pharmaceutical companies.
